Introduction
============

Gastrointestinal cancer, including gastric cancer (GC) and colorectal cancer (CRC), is a major health problem that accounts for a large proportion of all human malignancies;[@b1-ott-8-641] approximately 3.25 million people are diagnosed with the disease each year worldwide.[@b2-ott-8-641] Despite recent advances in the diagnosis and therapy of this disease, most gastrointestinal cancer patients present with advanced disease with poor prognoses and low survival rates. Chemotherapy for advanced gastrointestinal cancer has some advantages over best supportive care, including improved quality of life; however, survival does not increase dramatically, with the overall survival (OS) ranging from 6.0 to 12.0 months with chemotherapy.[@b3-ott-8-641] Combination treatment with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) is now considered the standard treatment for GC and CRC, with a response rate of over 40% for first-line treatment.[@b4-ott-8-641] Oxaliplatin is a frequently used agent that is part of many chemotherapy regimens used to treat several gastrointestinal cancers. It is an organoplatinum complex that can produce both inter- and intra-strand platinum-DNA cross-links that, in turn, lead to the inhibition of DNA replication and transcription.[@b5-ott-8-641] However, oxaliplatin-based therapies have a critical drawback: tumor cell drug resistance. Although resistance to chemotherapy is multifactorial, DNA repair plays a key role in the resistance of tumors to oxaliplatin.

Excision repair cross-complementing 1 (*ERCC1*) is a gene encoding a protein of the nucleotide excision repair (NER) complex, which is a group of proteins that are able to repair the DNA damage induced by substances forming adducts, such as platinum.[@b6-ott-8-641] In the past years, the role of single-nucleotide polymorphisms (SNPs) in *ERCC1* as predictive factors for treatment outcomes in oxaliplatin-based chemotherapy-treated gastrointestinal cancer patients has been extensively investigated; rs11615 is a common SNP in the coding region of the *ERCC1* gene, and its polymorphisms might predict patients' response to oxaliplatin and the survival of patients with gastrointestinal cancer. However, other studies have suggested that there is no association of the *ERCC1* rs11615 polymorphism with the clinical outcomes of gastrointestinal cancer patients receiving oxaliplatin-based chemotherapy.[@b7-ott-8-641],[@b8-ott-8-641] Thus, we performed this meta-analysis to evaluate the effects of the *ERCC1* rs11615 (C/T) polymorphisms on the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancer patients by assessing therapeutic response, progression-free survival (PFS), and OS.

Materials and methods
=====================

Publication search
------------------

This meta-analysis adheres to the relevant criteria of the preferred reporting items for systemic reviews and meta-analyses statement.[@b9-ott-8-641] The PubMed database was searched for material published in English; the latest search was updated on December 20, 2014. The searching strategy consisted of combinations of medical subheadings and key words, such as "gastrointestinal cancer" or "gastric cancer" or "colorectal cancer" and "excision repair cross-complementing 1" or "ERCC1" or "ERCC1 rs11615" and "polymorphisms, single-nucleotide polymorphisms" or "polymorphism" and "oxaliplatin." All references cited in the original studies or review articles concerning the relevant topic were retrieved to broaden the search for relevant publications.

Inclusion and exclusion criteria
--------------------------------

In this meta-analysis, publications of studies that met the following criteria were included: 1) inclusion of gastrointestinal cancer patients (GC and CRC); 2) investigation of the relationship between the *ERCC1* rs11615 polymorphism and response to chemotherapy or survival; 3) restriction of the regimen to oxaliplatin-based chemotherapy for investigation of the response to chemotherapy; 4) primary outcomes of interest of objective response, PFS, or OS; and 5) available data for quantitative synthesis, namely, genotype distribution data for response or hazard ratios (HRs) and 95% confidence intervals (CIs) for survival. The following exclusion criteria were used: 1) oxaliplatin-based chemotherapy was used as neoadjuvant treatment; 2) abstracts and reviews; 3) studies without available or exact data; 4) written in a non-English language; and 5) repeated or overlapping publications.

Data extraction
---------------

Two authors independently extracted the following items from all of the included studies: name of the first author, publication year of the article, country or area, tumor types (GC or CRC), number of patients, chemotherapy regimens, and genotyping method and outcomes. In addition, the response to chemotherapy according to genotype, HRs for OS and PFS, and their 95% CIs were collected for statistical analysis. We resolved any discrepancies through discussion or by consultation with a third person.

Statistical analysis
--------------------

Pooled odds ratio (OR) and corresponding 95% CIs were calculated to estimate the association strength of the *ERCC1* rs11615 polymorphism (mutant gene vs wild-type gene, TT + CT vs CC) with the response to oxaliplatin-based chemotherapy. PFS and OS were evaluated by using pooled Cox proportional HRs and 95% CIs. A chi-square-based *Q*-test was used to test the assumption of heterogeneity. *P*\>0.1 for the *Q*-test suggested a lack of heterogeneity among studies and required the use of the fixed-effects model (the Mantel--Haenszel method) to estimate the pooled OR of all studies. Otherwise, the random effects model was used. Statistical analyses were performed using STATA statistical software (Version 10.0, StataCorp LP, College Station, TX, USA). *P*\<0.05 was considered statistically significant, and all *P*-values were two sided.

Results
=======

Characteristics of studies
--------------------------

In this meta-analysis, 22 studies were identified to evaluate the relationship between the *ERCC1* rs11615 polymorphism and the clinical outcomes of oxaliplatin-based chemotherapy in GC and CRC patients.[@b10-ott-8-641]--[@b31-ott-8-641] A total of 3,014 patients with gastrointestinal cancer were enrolled in this study, including 1,242 with GC and 1,772 with CRC. There were 12 studies from Asian populations[@b11-ott-8-641],[@b12-ott-8-641],[@b16-ott-8-641]--[@b19-ott-8-641],[@b21-ott-8-641]--[@b24-ott-8-641],[@b26-ott-8-641],[@b28-ott-8-641] and 10 from Caucasian populations.[@b10-ott-8-641],[@b13-ott-8-641]--[@b15-ott-8-641],[@b20-ott-8-641],[@b25-ott-8-641],[@b27-ott-8-641],[@b29-ott-8-641]--[@b31-ott-8-641] Oxaliplatin-based chemotherapy was investigated in all studies, and FOLFOX was the most popular regimen. The most common genotyping methods were polymerase chain reaction and restriction fragment length polymorphism analysis. Characteristics of the eligible studies are summarized in [Table 1](#t1-ott-8-641){ref-type="table"}.

Association between the *ERCC1* rs11615 polymorphism and therapeutic response
-----------------------------------------------------------------------------

Fourteen studies including 1,879 patients qualified for analysis of the association between the *ERCC1* rs11615 polymorphism and therapeutic response in GC and CRC patients. In the dominant model, the mutant gene was not associated with the objective response for all patients (TT + CT vs CC: OR =1.09, *P*=0.337, 95% CI =0.92--1.28) ([Figure 1](#f1-ott-8-641){ref-type="fig"}). However, stratified analysis by ethnicity showed a significant difference in the estimates of the effect between Asians and Caucasians, with the T allele being associated with a significantly lower objective response rate in Asians (TT + CT vs CC: OR =1.25, *P*\<0.001, 95% CI =1.14--1.38). In addition, in a stratified analysis according to tumor site, the mutant gene was associated with the objective response in GC patients (TT + CT vs CC: OR =1.18, *P*=0.004, 95% CI =1.05--1.38) ([Table 2](#t2-ott-8-641){ref-type="table"}).

Association between the *ERCC1* rs11615 polymorphism and PFS
------------------------------------------------------------

Data from 13 included studies (including 1,464 patients) were applicable for the analysis. As shown in [Figure 2](#f2-ott-8-641){ref-type="fig"}, the T allele was associated with a significant increase in the risk of shorter PFS in all patients (TT + CT vs CC: HR =1.22, *P*\<0.001, 95% CI =0.93--1.51). Similarly, we also performed stratified analysis by ethnicity and the tumor site, as shown in [Table 2](#t2-ott-8-641){ref-type="table"}.

Association between the *ERCC1* rs11615 polymorphism and OS
-----------------------------------------------------------

Fourteen studies including 2,078 subjects were included in the final analysis. There was a significant effect of the *ERCC1* rs11615 polymorphism on OS in all patients (TT + CT vs CC: HR =1.12, *P*\<0.001, 95% CI =0.85--1.40) ([Figure 3](#f3-ott-8-641){ref-type="fig"}). In subgroup analysis stratified by ethnicity and tumor site, the significant differences were retained, as shown in [Table 2](#t2-ott-8-641){ref-type="table"}.

Discussion
==========

Oxaliplatin-based chemotherapy is the primary therapeutic option for gastrointestinal cancer, especially for advanced or relapsed cancer. The mechanism of action of platinum agents is based on the formation of DNA adducts that result in the alteration of the DNA structure and, eventually, the inhibition of DNA replication and transcription.[@b32-ott-8-641] Hence, the expression of genes involved in the mechanisms of DNA repair has been studied as a possible predictive factor in patients treated with platinum-based chemotherapy.[@b33-ott-8-641] ERCC1, which has a variety of gene forms, is the lead enzyme in the NER DNA repair pathway.[@b34-ott-8-641] The DNA repair system plays a vital role in maintaining the stability of cellular functions and genomic integrity through the reversal of the DNA damage induced by various endogenous and/or exogenous factors, including therapeutic agents; therefore, host DNA repair capacity may contribute to cancer patient outcomes.[@b35-ott-8-641] One possible theory postulates that in the absence of platinum therapy, poor DNA repair may result in more biologically aggressive tumors through their susceptibility to greater genetic aberrations over time, resulting in worse outcomes.[@b36-ott-8-641]

The different polymorphisms of *ERCC1* may be related to the effect of chemotherapy in cancer patients. *ERCC1* rs11615 (C to T), belonging to the NER pathway, is associated with its diminished expression levels (mRNA and protein), with downstream functional consequences in the repair of cisplatin-induced DNA lesions. Recently, the *ERCC1* rs11615 gene polymorphism was shown to provide better prognostic information for cancer patients treated with platinum-based chemotherapy, including those with non-small cell lung cancer, ovarian cancer, testicular germ cell tumors, and gastrointestinal cancer.[@b37-ott-8-641]--[@b40-ott-8-641] Previous studies have revealed that *ERCC1* rs11615 genotypes are associated with the clinical outcome of GC or CRC patients who receive oxaliplatin-based chemotherapy, but the end results of these studies are not consistent, and current evidence is insufficient to confirm a statistically significant correlation. Some references describing association of rs11615 with ERCC1 diminished expression.[@b7-ott-8-641],[@b8-ott-8-641],[@b25-ott-8-641],[@b29-ott-8-641],[@b31-ott-8-641] This meta-analysis examined the association between the *ERCC1* rs11615 polymorphism and the clinical outcomes of gastric and CRCs that were treated by oxaliplatin-based chemotherapy. Therapeutic response, PFS, and OS were used as the main parameters. We found no statistical evidence for an association between two *ERCC1* rs11615 SNPs and the objective response for all patients. However, stratified analysis indicated the *ERCC1* rs11615 T allele was a biomarker of low therapeutic response in Asian patients and GC patients. At the same time, our meta-analysis provided evidence that the *ERCC1* rs11615 polymorphism was associated with PFS or OS. Notably, there was an apparent ethnic discrepancy in the prognostic value between Asians and Caucasians, and statistical tests also confirmed the existence of ethnic differences in the estimates of the effect of the *ERCC1* allele. This discrepancy could be explained by the fact that the treatment outcome of platinum agents may be influenced by gene--gene interactions in different genetic backgrounds and gene--environment interactions in different lifestyles. As the previous studies gave controversial results, there may be some other reasons, such as the following: 1) different pathological types (GC and CRC) may produce different results; 2) there was different incidences of GC or CRC in different regions of worldwide, for example, higher incidence of GC in East Asia; 3) the positive result of some studies might be attributed to small sample size; 4) the other factors of population included cannot be analyzed in detail, such as age, sex, smoking, and drinking status, which could make the result masked; and 5) some studies are hospital-based design, which would not represent the people who live in a certain region.

Attention should be paid to the limitations of the meta-analysis, although some effort was made to perform a precise and comprehensive analysis. First, there are very few studies comparing Asians and Caucasians, with even fewer involving the black population. Further, with original data lacking for every study, we could only present an extensive subgroup analysis. In addition, the differences in national characteristics in different regions are influencing factors in the study results. Oxaliplatin is used with 5-fluorouracil in the regimen, and not as a single compound, and owing to the limited available publications on the subject, the latent gene--gene associations between NER variants and folate-metabolizing gene variants still cannot be investigated. Finally, some confounding factors such as sex, age, TNM stage, and chemotherapy regimens can never change the results based on the initial data.

To summarize, polymorphisms of *ERCC1* rs11615 are closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy. Future studies with larger sample sizes using multivariant analyses may provide more persuasive data on this putative association.
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###### 

Study characteristics

  Study                                     Area                         N     Tumor types   Genotyping method   Chemotherapy regimen   Outcome
  ----------------------------------------- ---------------------------- ----- ------------- ------------------- ---------------------- -------------
  Martinez-Balibrea et al[@b10-ott-8-641]   Spain                        95    mCRC          PCR-RFLP            FOLFOX or XELOX        PFS
  Chang et al[@b11-ott-8-641]               Taiwan                       168   CRC           PCR-RFLP            FOLFOX                 TR, PFS, OS
  Chen et al[@b12-ott-8-641]                Taiwan                       166   mCRC          PCR-RFLP            FOLFOX                 TR, OS
  Chua et al[@b13-ott-8-641]                Australia                    118   mCRC          PCR-RFLP            FOLFOX                 PFS, OS
  Goekkurt et al[@b14-ott-8-641]            Germany                      134   GC            PCR-RFLP            FOLFOX                 TR
  Etienne-Grimaldi et al[@b15-ott-8-641]    France                       117   CRC           PCR-RFLP            FOLFOX                 TR, PFS, OS
  Huang et al[@b16-ott-8-641]               People's Republic of China   89    GC            PCR-LDR             FOLFOX                 PFS, OS
  Huang et al[@b17-ott-8-641]               People's Republic of China   102   GC            PCR-LDR             FOLFOX                 PFS, OS
  Keam et al[@b18-ott-8-641]                Korea                        73    GC            PCR-RFLP            FOLFOX                 TR, PFS, OS
  Kumamoto et al[@b19-ott-8-641]            Japan                        63    mCRC          PCR-RFLP            FOLFOX                 TR
  Lamas et al[@b20-ott-8-641]               Spain                        72    mCRC          PCR-RFLP            FOLFOX                 TR
  Li et al[@b21-ott-8-641]                  People's Republic of China   335   CRC           PCR-RFLP            FOLFOX                 OS
  Liang et al[@b22-ott-8-641]               People's Republic of China   113   CRC           TaqMan-PCR          FOLFOX or XELOX        TR, PFS, OS
  Liu et al[@b23-ott-8-641]                 People's Republic of China   116   GC            TaqMan-PCR          FOLFOX                 PFS, OS
  Lu et al[@b24-ott-8-641]                  People's Republic of China   447   GC            TaqMan-PCR          FOLFOX                 TR, OS
  Paré et al[@b25-ott-8-641]                Spain                        126   CRC           TaqMan-PCR          FOLFOX                 TR, PFS, OS
  Qi et al[@b26-ott-8-641]                  People's Republic of China   206   GC            RT-PCR              FOLFOX                 TR
  Ruzzo et al[@b27-ott-8-641]               Italy                        166   CRC           PCR-RFLP            FOLFOX                 PFS
  Seo et al[@b28-ott-8-641]                 Korea                        75    GC            PCR-RFLP            FOLFOX                 TR, PFS, OS
  Spindler et al[@b29-ott-8-641]            Denmark                      66    CRC           PCR                 XELOX                  TR
  Stoehlmacher et al[@b30-ott-8-641]        USA                          106   CRC           PCR-RFLP            FOLFOX                 PFS, OS
  Viguier et al[@b31-ott-8-641]             France                       61    CRC           PCR                 FOLFOX                 TR

**Abbreviations:** N, number of patients; mCRC, metastatic colorectal cancer; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; FOLFOX, 5-fluorouracil plus oxaliplatin; XELOX, capecitabine plus oxaliplatin; PFS, progression-free survival; CRC, colorectal cancer; TR, therapeutic response; OS, overall survival; GC, gastric cancer; PCR-LDR, polymerase chain reaction-ligation detection reaction; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction.

###### 

Association between the *ERCC1* rs11615 polymorphism and therapeutic response, PFS, and OS

                         Studies   OR/HR (95% CI)      *Z*-value   *P*-value   *I*^2^ (%)
  ---------------------- --------- ------------------- ----------- ----------- ------------
  Therapeutic response                                                         
   Asian                 8         1.25 (1.14, 1.38)   4.58        \<0.001     0.0
   Caucasian             6         0.75 (0.54, 1.04)   1.73        0.083       56.8
   GC                    5         1.18 (1.05, 1.38)   2.85        0.004       0.0
   CRC                   9         0.98 (0.74, 1.30)   0.14        0.889       74.4
  PFS                                                                          
   Asian                 8         1.49 (1.05, 1.92)   6.72        \<0.001     58.9
   Caucasian             5         0.91 (0.59, 1.24)   6.74        \<0.001     59.2
   GC                    5         1.25 (0.82, 1.67)   5.73        \<0.001     48.8
   CRC                   8         1.21 (0.80, 1.62)   5.83        \<0.001     74.2
  OS                                                                           
   Asian                 10        1.21 (0.86, 1.55)   6.87        \<0.001     61.5
   Caucasian             4         1.02 (0.44, 1.60)   3.44        0.001       61.1
   GC                    6         1.15 (0.71, 1.60)   5.05        \<0.001     59.2
   CRC                   8         1.17 (0.76, 1.58)   5.58        \<0.001     65.4

**Abbreviations:** *ERCC1*, excision repair cross-complementing 1; PFS, progression-free survival; OS, overall survival; OR/HR, odds ratio/hazard ratio; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; PFS, progression-free survival; OS, overall survival.
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